Exercise Interventions in Obstructive Sleep Apnea Syndrome
3 juin 2026 mis à jour par: Melis Usul, Istanbul University - Cerrahpasa
The Effect of Exercise Snacks and Aerobic Exercise on Circadian Rhythm and Functional Capacity in Individuals With Obstructive Sleep Apnea Syndrome
Obstructive Sleep Apnea Syndrome (OSA) is a condition characterized by repeated pauses or reductions in breathing during sleep, which can negatively affect sleep quality, daytime functioning, and physical capacity.
Although regular exercise is known to have beneficial effects in OSA, the effects of different exercise approaches on circadian rhythm and functional capacity have not been sufficiently investigated.The primary aim of this study is to compare the effects of exercise snacking and aerobic exercise on circadian rhythm and functional capacity in individuals with OSA, in comparison with a control group.
The secondary aim is to evaluate the effects of these exercise interventions on peripheral muscle strength, fatigue level, body composition, quality of life, and physical activity level.Participants will be randomly assigned to three groups: an aerobic exercise group, an exercise snacking group, and a control group.
While the exercise groups will follow their respective intervention programs, the control group will continue their routine treatment.This study aims to answer whether exercise snacking, which consists of short bouts of exercise distributed throughout the day, may be an alternative or complementary approach to traditional aerobic exercise in individuals with OSA.
In addition, this study aims to be the first randomized controlled trial evaluating the effects of exercise snacking on circadian rhythm and functional capacity in individuals with OSA.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
Obstructive Sleep Apnea Syndrome (OSA) is a common sleep-related breathing disorder characterized by repeated episodes of partial or complete upper airway obstruction during sleep.
It is associated with intermittent hypoxia, sleep fragmentation, and increased risk of cardiovascular and metabolic comorbidities.
Emerging evidence also suggests a bidirectional relationship between OSA and circadian rhythm disruption, where each condition may negatively influence the other.
Therefore, improving circadian regulation may be an important therapeutic target in OSA management.Exercise is a widely accepted non-pharmacological intervention in OSA due to its potential benefits on sleep-related outcomes and overall health.
However, adherence to conventional structured exercise programs may be limited due to time constraints and sustainability issues.
Recently, exercise snacking-short bouts of exercise performed throughout the day-has been proposed as a time-efficient and more feasible alternative to traditional exercise approaches.
This strategy may improve long-term adherence by integrating physical activity into daily routines without requiring supervised sessions.Despite its potential advantages, evidence regarding the effects of exercise snacking in individuals with OSA is currently limited.
In addition, there is a lack of randomized controlled trials comparing exercise snacking with aerobic exercise while also evaluating circadian rhythm-related outcomes in this population.This study is designed as a prospective, single-blind, randomized controlled trial.
A total of 39 individuals diagnosed with moderate to severe OSA will be randomly assigned to three groups: aerobic exercise group, exercise snacking group, and control group.
The intervention period will last 8 weeks.
The aerobic exercise group will perform supervised aerobic and resistance-based training, while the exercise snacking group will perform short, home-based exercise bouts distributed across the day.
The control group will continue usual medical care and receive a single session of sleep hygiene education.The study will evaluate the effects of the interventions on circadian rhythm and functional capacity as primary outcomes, and on secondary outcomes including fatigue, muscle strength, body composition, physical activity level, insomnia severity, and quality of life.
Assessments will be performed at baseline and after the 8-week intervention period.
Type d'étude
Interventionnel
Inscription (Estimé)
39
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Melis Usul, PhD student
- Numéro de téléphone: +(90)5364667235
- E-mail: melisausul1999@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Gökşen Kuran Aslan, Professor
- Numéro de téléphone: +(90)5324095246
- E-mail: goksenkuran@yahoo.com
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye)
- Istanbul University-Cerrahpaşa, Department of Physiotherapy and Rehabilitation, Istanbul, Türkiye
-
Contact:
- Melis Usul
- Numéro de téléphone: +(90)5364667235
- E-mail: melisausul1999@gmail.com
-
Chercheur principal:
- Melis USUL
-
Sous-enquêteur:
- Gökşen Kuran Aslan
-
Sous-enquêteur:
- Esen Kıyan
-
Sous-enquêteur:
- Zeynep Banu Güngör
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Individuals diagnosed with OSAHS (AHI ≥ 15) confirmed by polysomnography, with moderate or severe disease, who have been receiving CPAP therapy for at least 3 months.
- Adults aged 30-65 years.
- No participation in any regular exercise program within the last 6 months.
Exclusion Criteria:
- Individuals with OSAHS and a body mass index (BMI) > 35 kg/m²
- Severe chronic pulmonary disease
- Neurological or musculoskeletal disorders that prevent exercise
- Unstable cardiovascular conditions
- Unstable metabolic conditions
- Severe psychiatric disorders such as bipolar disorder or schizophrenia
- Pregnancy or breastfeeding
- Individuals working night shifts or with schedules that may cause jet lag
- Use of steroid or hormone therapy
- Use of melatonin or sleep-regulating medications within the last 3 months
- Presence of acute infection or inflammation
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Aerobic Exercise Group
Aerobic Exercise Training
|
Participants in the aerobic exercise group will undergo an 8-week supervised aerobic exercise program on a cycle ergometer, performed twice per week.
Each session will last approximately 30-45 minutes and will include a 5-minute low-intensity warm-up and a 5-minute cool-down period.
Exercise intensity will be set at a moderate level according to the Karvonen method.
The main exercise duration will be progressively increased throughout the intervention period: 20 minutes during weeks 1-2, 25 minutes during weeks 3-4, 30 minutes during weeks 5-6, and 35 minutes during weeks 7-8.
Participants' heart rate will be monitored during exercise sessions, and perceived exertion will be assessed using the Borg Rating of Perceived Exertion Scale.In addition, all participants will be instructed to perform resistance exercises once per week.
The exercises will target the upper extremity, lower extremity, and core muscles and will consist of three different exercises.
|
|
Expérimental: Exercise Snacks Group
Exercise Snacking
|
The exercises will be performed by participants at home and supervised by the researcher.
Since progression of each exercise will be implemented every two weeks, participants will be scheduled to attend the clinic every two weeks, where the exercises will be demonstrated.
Each session will consist of six different exercises (squat, heel raises, marching in place, jumping jacks, upright row, and chest press).
Each exercise will be performed for 1 minute, followed by a 1-minute seated rest interval.
Thus, each session will last approximately 12 minutes.
Exercise progression will be applied every two weeks for each exercise.
During the sessions, participants will monitor their heart rate and oxygen saturation.
An oxygen saturation level below 90% will be defined as the exercise termination criterion.
Participants will be provided with a daily logbook to record completion of exercise snacking sessions.
|
|
Aucune intervention: Control Group (Usual Care)
Usual Care
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI) Total Score
Délai: From baseline to the end of the intervention at 8 weeks
|
Sleep quality assessed using the Pittsburgh Sleep Quality Index.
Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.
|
From baseline to the end of the intervention at 8 weeks
|
|
Epworth Sleepiness Scale (ESS) Total Score
Délai: From baseline to the end of the intervention at 8 weeks
|
Daytime sleepiness will be assessed using the Epworth Sleepiness Scal (ESS).Scores ≥10 indicate excessive daytime sleepiness.
|
From baseline to the end of the intervention at 8 weeks
|
|
Morningness-Eveningness Questionnaire (MEQ) Total Score
Délai: From baseline to the end of the intervention at 8 weeks
|
Circadian rhythm preference will be assessed using the Morningness-Eveningness Questionnaire (MEQ).The questionnaire consists of 19 items evaluating sleep-wake preferences and chronotype.Higher scores indicate morningness, whereas lower scores indicate eveningness.
|
From baseline to the end of the intervention at 8 weeks
|
|
Serum Cortisol Level
Délai: From baseline to the end of the intervention at 8 weeks
|
Fasting morning serum cortisol concentration measured by chemiluminescent immunoassay.
|
From baseline to the end of the intervention at 8 weeks
|
|
Serum Thyroid-Stimulating Hormone (TSH) Level
Délai: From baseline to the end of the intervention at 8 weeks
|
Fasting morning serum TSH concentration measured by chemiluminescent immunoassay.
|
From baseline to the end of the intervention at 8 weeks
|
|
Functional Capacity
Délai: From baseline to the end of the intervention at 8 weeks
|
Functional capacity will be assessed using the 6-Minute Walk Test (6MWT) according to American Thoracic Society criteria.
Walking distance covered within 6 minutes will be recorded in meters.
Higher values indicate better functional capacity.
|
From baseline to the end of the intervention at 8 weeks
|
|
Total Sleep Time (Sleep Diary)
Délai: From baseline to the end of the intervention at 8 weeks
|
Total sleep time will be assessed subjectively using a sleep diary based on the Consensus Sleep Diary (CSD).
Participants will complete the diary for 7 consecutive days at baseline and at week 8.
Total sleep time will be recorded in minutes.
|
From baseline to the end of the intervention at 8 weeks
|
|
Total Sleep Time (Wearable Device)
Délai: From baseline to the end of the intervention at 8 weeks
|
Total sleep time will be objectively assessed using a Polar Unite wearable activity tracker with Sleep Plus Stages™ algorithm.
Measurements will be collected over 3 consecutive nights at baseline and at week 8.
Total sleep time will be expressed in minutes.
|
From baseline to the end of the intervention at 8 weeks
|
|
Sleep Efficiency (Wearable Device)
Délai: From baseline to the end of the intervention at 8 weeks
|
Sleep efficiency will be assessed using a Polar Unite wearable activity tracker with Sleep Plus Stages™ algorithm.
Measurements will be collected over 3 consecutive nights at baseline and at week 8. Sleep efficiency will be expressed as percentage (%).
|
From baseline to the end of the intervention at 8 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Insomnia Severity
Délai: From baseline to the end of the intervention at 8 weeks
|
Insomnia severity will be assessed using the Insomnia Severity Index (ISI).
The ISI consists of 7 items scored from 0 to 4, with a total score ranging from 0 to 28.
Higher scores indicate greater insomnia severity.
Scores ≥10 indicate clinically significant insomnia.
|
From baseline to the end of the intervention at 8 weeks
|
|
Waist Circumference (cm)
Délai: From baseline to the end of the intervention at 8 weeks
|
Waist circumference measured using a non-elastic tape measure.
|
From baseline to the end of the intervention at 8 weeks
|
|
Hip Circumference (cm)
Délai: From baseline to the end of the intervention at 8 weeks
|
Hip circumference measured using a non-elastic tape measure.
|
From baseline to the end of the intervention at 8 weeks
|
|
Neck Circumference (cm)
Délai: From baseline to the end of the intervention at 8 weeks
|
Neck circumference measured using a non-elastic tape measure.
|
From baseline to the end of the intervention at 8 weeks
|
|
Muscle Mass (kg)
Délai: From baseline to the end of the intervention at 8 weeks
|
Muscle mass assessed using bioelectrical impedance analysis (BIA).
|
From baseline to the end of the intervention at 8 weeks
|
|
Body Fat Percentage (%)
Délai: From baseline to the end of the intervention at 8 weeks
|
Body fat percentage assessed using bioelectrical impedance analysis (BIA).
|
From baseline to the end of the intervention at 8 weeks
|
|
Bone Mass (kg)
Délai: From baseline to the end of the intervention at 8 weeks
|
Bone mass assessed using bioelectrical impedance analysis (BIA).
|
From baseline to the end of the intervention at 8 weeks
|
|
Body Water Percentage (%)
Délai: From baseline to the end of the intervention at 8 weeks
|
Body water percentage assessed using bioelectrical impedance analysis (BIA).
|
From baseline to the end of the intervention at 8 weeks
|
|
Fatigue Severity
Délai: From baseline to the end of the intervention at 8 weeks
|
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS).
The FSS consists of 9 items scored from 1 to 7. Higher scores indicate greater fatigue severity.
Mean scores ≥4 indicate clinically significant fatigue.
|
From baseline to the end of the intervention at 8 weeks
|
|
Peripheral Muscle Strength
Délai: From baseline to the end of the intervention at 8 weeks
|
Peripheral muscle strength (quadriceps, biceps brachii, and handgrip strength) will be assessed using a hand-held dynamometer and handgrip dynamometer.
Higher values indicate greater muscle strength.
|
From baseline to the end of the intervention at 8 weeks
|
|
Physical Activity Level
Délai: From baseline to the end of the intervention at 8 weeks
|
Physical activity level will be assessed using a pedometer.
Average daily step count (steps/day) will be recorded.
Higher values indicate greater physical activity.
|
From baseline to the end of the intervention at 8 weeks
|
|
Health-related quality of life (Functional Outcomes of Sleep Questionnaire, FOSQ)
Délai: From baseline to the end of the intervention at 8 weeks
|
Quality of life will be assessed using the Functional Outcomes of Sleep Questionnaire (FOSQ).
The questionnaire consists of 26 items with total scores ranging from 4 to 16. Lower scores indicate greater impairment in sleep-related quality of life.
|
From baseline to the end of the intervention at 8 weeks
|
|
Patient Global Impression of Change
Délai: At the end of the intervention (8 weeks)
|
Perceived clinical improvement will be assessed using the Patient Global Impression of Change (PGIC).
The scale ranges from 1 (very much improved) to 7 (very much worse).
Lower scores indicate greater perceived improvement.
|
At the end of the intervention (8 weeks)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: MELİS USUL, Istanbul University - Cerrahpasa
- Directeur d'études: Gökşen Kuran Aslan, Professor, Istanbul University - Cerrahpasa
- Chaise d'étude: Esen Kıyan, Professor, Istanbul University Faculty of Medicine
- Chaise d'étude: Zeynep Banu Güngör, Professor, Istanbul University - Cerrahpasa
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 septembre 2026
Achèvement primaire (Estimé)
1 décembre 2027
Achèvement de l'étude (Estimé)
1 février 2028
Dates d'inscription aux études
Première soumission
31 mai 2026
Première soumission répondant aux critères de contrôle qualité
3 juin 2026
Première publication (Réel)
8 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
3 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 3RQX7PDq
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .